Coronado Industries on Track with Banner Year Prediction; Focus is on Sales.

FOUNTAIN HILLS, Ariz. -- Coronado Industries, Inc. (OTCBB:CDIK), the manufacturers of unique proprietary pneumatic devices for the non-invasive treatment of glaucoma and ocular hypertension, prediction of 2005 to be a banner year is on track.

We are making great strides in expanding our European distribution network.

The addition of a Polish contract last week is a welcome addition. Sales are moving ahead nicely under our current contracts -- 22 units were sold and delivered in the last 30 days driving our total number of units shipped to 138.

As reported in a February news release -- each unit actively used in the field should produce approximately $5,000 to $7,000 revenue per year in ring sales to Coronado Industries.

It is a real snowball effect says Richard Smith CEO of Coronado Industries. When a doctor treats a patient with PNT he uses a pre sterilized pre-packaged disposable ring. The patient will then have additional treatments every 3-4 months for as long as they are treated, using a new ring each time.

Anytime a unit is sold and delivered to a doctors office or hospital we have access to hundreds of patients -- who will require multiple treatments for years to come.

The number of units in the field are growing each month. With the addition of new contracts soon to come -- the ring sales will continue to compound year after year.

With our patents covering not only the device and rings -- but also the medical procedure itself, we feel that our growth and profitability should not be hindered by competition.

On another note -- to help Coronado Industries reduce outstanding debt, it was decided by its officers to forgive approximately $750,000 in back salaries owed to them as indicated in the recently filed 10Q.

Coronado Industries through its wholly owned subsidiary, Ophthalmic International, is focused on the development and commercialization of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma which are open angle and pigmentary as well as for the treatment of ocular hypertension.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.